trending Market Intelligence /marketintelligence/en/news-insights/trending/N81bAOqY9BKGUG7RIe6oEA2 content esgSubNav
In This List

Medicure files patent infringement against Nexus Pharmaceuticals

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Medicure files patent infringement against Nexus Pharmaceuticals

Medicure Inc. filed a suit against Nexus Pharmaceuticals Inc. for allegedly infringing its patent for drug Aggrastat.

Aggrastat, or tirofiban hydrochloride, is used to reduce blood clots in patients with acute coronary syndrome.

Medicure said it filed the case after Nexus sought the U.S. Food and Drug Administration's approval to market a generic version of Medicure's medicine. The patent for Aggrastat has not yet expired.

Medicure, a Canada-based pharmaceutical company, filed the case in the U.S. District Court for the District of Northern District of Illinois through its Medicure International Inc. unit.

Previously, Medicure sued India's Gland Pharma Ltd. for infringing the patent for Aggrastat. The case was settled in August.